By Kim Polacek, APR, CPRC - June 02, 2023
If you want to learn about the newest cancer therapies or innovative prevention and detection strategies, look no further than the American Society of Clinical Oncology (ASCO) Annual Meeting. The event brings together more than 40,000 participants to discuss the latest advancements in cancer care and research, making it one of the largest, most diverse cancer conferences in the world.
This year’s theme is “Partnering with Patients: The Cornerstone of Cancer Care and Research.” The multiday meeting will feature over 200 sessions highlighting such topics as optimizing patient care, improving access to care and development of innovative therapies.
More than 5,500 abstracts will be presented during the meeting. Moffitt physician scientists will be part of those oral, poster and educational sessions, sharing abstract data and information on various topics including clinical trials evaluating new immunotherapies, the impact of racial disparities on cancer care and liquid biopsies to detect certain cancers. You can learn more about Moffitt’s scientific presentations at ASCO at www.Moffitt.org/ASCO and in the stories below.
Read Moffitt’s ASCO 2023 Stories
Predicting Response to Herpes Virus in Triple-Negative Breast Cancer Patients
New study identifies genetic biomarkers that correlate with higher response rates
Ramping Up the Immune System to Fight Breast Cancer
Clinical trial led by Moffitt evaluates combination immunotherapy for HER2 positive metastatic disease
Comparing Therapy Options for Melanoma In-Transit Metastases
New retrospective study is first direct comparison of first-line treatment
Can Viruses Be Used to Treat Lung Cancer?
Oncolytic virus therapy stimulates immune system to target cancer cells
Molecular Risk Model Better Predicts Outcomes in Rare Blood Cancer
New model can help dictate treatment decisions in chronic myelomonocytic leukemia
Combination Therapy Shows Mixed Results in First Randomized Trial for Lung Cancer
Tumor shrinkage is a positive sign, but overall survival rates did not improve
